tradingkey.logo
tradingkey.logo
Search

Century Therapeutics Inc

IPSC
Add to Watchlist
2.020USD
-0.170-7.76%
Close 07-31 16:00ETQuotes delayed by 15 min
364.32MMarket Cap
LossP/E TTM

IPSC Income Statement

You can find the annual or quarterly income statement of Century Therapeutics Inc here for insights into the performance and operational efficiency of Century Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q3
FY2020Q2
FY2020Q1
Total revenue
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
12667.72%109.16M
1457.09%4.17M
434.46%791.00K
678.79%771.00K
-50.29%855.00K
-48.56%268.00K
-93.35%148.00K
-92.91%99.00K
62.57%1.72M
--521.00K
--2.22M
--1.40M
--1.06M
----
----
----
----
----
----
----
Revenue
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
12667.72%109.16M
1457.09%4.17M
434.46%791.00K
678.79%771.00K
-50.29%855.00K
-48.56%268.00K
-93.35%148.00K
-92.91%99.00K
62.57%1.72M
--521.00K
--2.22M
--1.40M
--1.06M
----
----
----
----
----
----
----
Operating expenses
-32.31%23.68M
-44.38%20.65M
-17.48%29.36M
-2.43%34.66M
8.78%34.99M
20.22%37.13M
11.98%35.58M
14.76%35.53M
-4.84%32.16M
-8.70%30.89M
-6.44%31.77M
-5.47%30.96M
18.62%33.80M
20.93%33.83M
31.50%33.96M
42.25%32.75M
57.76%28.49M
--27.97M
96.69%25.83M
113.28%23.02M
80.75%18.06M
--13.13M
--10.79M
--9.99M
R&D expenses
-35.65%17.11M
-32.95%19.70M
-17.27%22.53M
-1.33%26.86M
13.49%26.58M
31.75%29.38M
19.48%27.23M
19.77%27.22M
-5.94%23.42M
-12.86%22.30M
-12.01%22.79M
-7.21%22.73M
17.47%24.90M
17.38%25.59M
32.50%25.90M
29.37%24.49M
37.87%21.20M
--21.80M
80.77%19.55M
123.16%18.93M
93.55%15.37M
--10.81M
--8.48M
--7.94M
Depreciation, depletion, and amortization
-6.74%3.00M
6.99%3.55M
-5.12%3.13M
-7.54%3.20M
-0.15%3.22M
-6.59%3.32M
-1.55%3.30M
5.81%3.46M
8.84%3.23M
22.19%3.55M
17.46%3.35M
87.61%3.27M
139.81%2.96M
157.71%2.91M
154.42%2.85M
72.33%1.74M
55.86%1.24M
--1.13M
164.39%1.12M
258.87%1.01M
296.50%793.00K
--424.00K
--282.00K
--200.00K
Operating profit
-131.93%-23.68M
37.34%-20.65M
15.60%-29.36M
0.26%-34.66M
336.92%74.18M
-7.64%-32.96M
-10.00%-34.79M
-12.63%-34.76M
2.41%-31.31M
8.07%-30.62M
0.35%-31.63M
1.58%-30.86M
-16.93%-32.08M
-19.06%-33.31M
-22.89%-31.74M
-36.18%-31.35M
-51.90%-27.44M
---27.97M
-96.69%-25.83M
-113.28%-23.02M
-80.75%-18.06M
---13.13M
---10.79M
---9.99M
Net non-operating interest income (expenses)
Non-operating interest income
-16.64%2.02M
-54.56%1.31M
-51.44%1.60M
-43.89%2.01M
-25.18%2.42M
-17.92%2.88M
-5.19%3.31M
17.14%3.58M
23.41%3.24M
--3.51M
--3.49M
--3.06M
--2.62M
----
----
----
----
----
----
----
----
----
----
----
Non-operating interest expense
----
----
----
----
----
--0.00
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-58.79%136.00K
28.66%404.00K
28.66%413.00K
15.84%373.00K
3.77%330.00K
0.00%314.00K
--321.00K
445.76%322.00K
--318.00K
--314.00K
--59.00K
--0.00
--0.00
Gains from sale of securities
----
----
----
----
----
----
----
----
----
----
----
----
----
1346.85%2.07M
890.71%1.39M
977.27%711.00K
803.57%253.00K
--143.00K
16.67%140.00K
-69.30%66.00K
-91.25%28.00K
--120.00K
--215.00K
--320.00K
Special income (expenses)
----
100.00%0.00
---6.76M
----
----
67.08%-4.33M
100.00%0.00
100.00%0.00
----
---13.14M
---4.00M
---4.22M
100.00%0.00
--0.00
--0.00
--0.00
---10.00M
--0.00
--0.00
100.00%0.00
----
--0.00
---4.72M
----
- Gains from disposal of fixed assets
----
----
---1.40M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
152.63%20.00K
-2.83%103.00K
496.80%1.49M
1041.67%113.00K
-445.45%-38.00K
806.67%106.00K
1983.33%250.00K
93.55%-12.00K
105.67%11.00K
---15.00K
--12.00K
---186.00K
---194.00K
----
----
----
----
----
----
----
----
----
----
----
Income before tax
-128.27%-21.64M
43.90%-19.24M
-10.21%-34.42M
-4.35%-32.54M
372.83%76.56M
14.83%-34.30M
2.78%-31.23M
3.57%-31.18M
6.64%-28.06M
-27.23%-40.27M
-4.57%-32.13M
-4.43%-32.34M
19.84%-30.06M
-12.43%-31.65M
-18.13%-30.72M
-33.07%-30.97M
-104.37%-37.50M
---28.15M
-99.00%-26.01M
-52.10%-23.27M
-89.68%-18.35M
---13.07M
---15.30M
---9.67M
Income tax
----
-103.83%-68.00K
100.00%0.00
----
-100.00%0.00
304.37%1.78M
-101.35%-8.00K
-97.68%22.00K
-99.92%1.00K
-2815.63%-869.00K
2268.00%592.00K
5177.78%950.00K
7450.00%1.21M
-25.58%32.00K
--25.00K
--18.00K
--16.00K
--43.00K
----
----
----
----
----
----
Income after tax
-128.27%-21.64M
46.85%-19.17M
-10.24%-34.42M
-4.27%-32.54M
372.82%76.56M
8.44%-36.07M
4.57%-31.23M
6.26%-31.21M
10.24%-28.06M
-24.35%-39.40M
-6.41%-32.72M
-7.43%-33.29M
16.66%-31.26M
-12.37%-31.68M
-18.22%-30.75M
-33.15%-30.99M
-104.45%-37.51M
---28.19M
-99.00%-26.01M
-52.10%-23.27M
-89.68%-18.35M
---13.07M
---15.30M
---9.67M
Net income from continuous operations
-128.27%-21.64M
46.85%-19.17M
-10.24%-34.42M
-4.27%-32.54M
372.82%76.56M
8.44%-36.07M
4.57%-31.23M
6.26%-31.21M
10.24%-28.06M
-24.35%-39.40M
-6.41%-32.72M
-7.43%-33.29M
16.66%-31.26M
-12.37%-31.68M
-18.22%-30.75M
-33.15%-30.99M
-104.45%-37.51M
---28.19M
-99.00%-26.01M
-52.10%-23.27M
-89.68%-18.35M
---13.07M
---15.30M
---9.67M
Net income attributable to controlling interests
-128.27%-21.64M
46.85%-19.17M
-10.24%-34.42M
-4.27%-32.54M
372.82%76.56M
8.44%-36.07M
4.57%-31.23M
6.26%-31.21M
10.24%-28.06M
-24.35%-39.40M
-6.41%-32.72M
-7.43%-33.29M
16.66%-31.26M
-12.37%-31.68M
-18.22%-30.75M
-33.15%-30.99M
-104.45%-37.51M
---28.19M
-99.00%-26.01M
-52.10%-23.27M
-89.68%-18.35M
---13.07M
---15.30M
---9.67M
Net income attributable to common shareholders
-128.27%-21.64M
46.85%-19.17M
-10.24%-34.42M
-4.27%-32.54M
372.82%76.56M
8.44%-36.07M
4.57%-31.23M
6.26%-31.21M
10.24%-28.06M
-24.35%-39.40M
-6.41%-32.72M
-7.43%-33.29M
16.66%-31.26M
-12.37%-31.68M
-18.22%-30.75M
-33.15%-30.99M
-104.45%-37.51M
---28.19M
-99.00%-26.01M
-52.10%-23.27M
-89.68%-18.35M
---13.07M
---15.30M
---9.67M
Basic earnings per share
-112.57%-0.11
48.00%-0.22
-7.99%-0.40
0.74%-0.38
297.58%0.89
35.69%-0.42
33.02%-0.37
32.34%-0.38
15.55%-0.45
-20.85%-0.66
-3.77%-0.55
-4.59%-0.56
18.88%-0.53
-6.11%-0.54
-11.09%-0.53
72.20%-0.54
72.49%-0.66
---0.51
72.67%-0.48
5.52%-1.93
-84.86%-2.39
---1.75
---2.05
---1.29
Diluted earnings per share
-112.58%-0.11
48.00%-0.22
-7.99%-0.40
0.74%-0.38
297.40%0.89
35.69%-0.42
33.02%-0.37
32.34%-0.38
15.55%-0.45
-20.85%-0.66
-3.77%-0.55
-4.59%-0.56
18.88%-0.53
-6.11%-0.54
-11.09%-0.53
72.20%-0.54
72.49%-0.66
---0.51
72.67%-0.48
5.52%-1.93
-84.86%-2.39
---1.75
---2.05
---1.29
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Century Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing IPSC stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Century Therapeutics Inc's revenue at year end?

Century Therapeutics Inc reported 109.16M in revenue for fiscal year 2025, up from 6.59M in the previous year.

What was Century Therapeutics Inc's net income for the year?

Century Therapeutics Inc posted -9.58M in net income for fiscal year 2025.

How much net income did Century Therapeutics Inc post in the last quarter?

Century Therapeutics Inc reported -21.64M in net income for the latest quarter。

What was Century Therapeutics Inc's annual operating profit?

Century Therapeutics Inc's operating income was -10.51M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.